论文部分内容阅读
为了评价重组人白介素-11(rhIL-11)治疗肿瘤患者化疗所致血小板减少的疗效和安全性,回顾性分析化疗后出现≤Ⅱ度血小板减少应用rhIL-11治疗的73例患者临床资料。化疗后血小板<75×109L-1应用rhIL-11治疗的73例恶性肿瘤患者,治疗持续时间为4~23 d(7.4±4.2),治疗有效率为93.2%,其中50例血小板<50×109L-1的患者中,治疗有效率为92.0%;血小板Ⅱ度(23例)和Ⅲ/Ⅳ度(50例)患者,应用rhIL-11治疗时的PLT数值分别为(62.8±6.1)×109和(39.8±18.6)×109L-1,治疗持续时间分别为4~9 d(5.0±1.4)和4~23 d(8.5±4.6),差异有统计学意义,P<0.05;rhIL-11开始治疗时血小板数值与疗效和用药时间均呈负相关,P均<0.05。不良反应为水肿、心悸、胸闷不适、肌肉关节疼痛、乏力、低热、结膜充血和心律失常(频发房性早博)。初步研究结果提示,rhIL-11治疗肿瘤患者化疗后血小板减少安全有效,早期应用能起到更佳的效果。
To evaluate the efficacy and safety of recombinant human interleukin-11 (rhIL-11) in the treatment of chemotherapy-induced thrombocytopenia in patients with cancer, the clinical data of 73 patients with ≤Ⅱ thrombocytopenia treated with rhIL-11 after chemotherapy were retrospectively analyzed. After chemotherapy, 73 cases of malignant tumors treated with rhIL-11 with a platelet count of <75 × 109L-1 had a duration of 4 ~ 23 days (7.4 ± 4.2) and a response rate of 93.2% .50 of them -1, the effective rate of treatment was 92.0%. The PLT values of patients with platelet Ⅱ (23 cases) and Ⅲ / Ⅳ (50 cases) treated with rhIL-11 were (62.8 ± 6.1) × 109 and (39.8 ± 18.6) × 109L-1, respectively. The duration of treatment was (5.0 ± 1.4) and (4 ± 3) days and 8.5 ± 4.6 days, with significant difference When the value of platelets and the efficacy and medication time were negatively correlated, P <0.05. Adverse reactions to edema, palpitations, chest tightness, discomfort, muscle and joint pain, fatigue, fever, conjunctival congestion and arrhythmia (frequent atrial premature beats). Preliminary results suggest that, rhIL-11 treatment of cancer patients after thrombocytopenia safe and effective, early application can play a better effect.